Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma

BACKGROUND: Thymic carcinoma is a rare cancer with minimal evidence of a survival benefit following chemotherapy. An oral fluoropyrimidine of S-1, however, is the recommended active cytotoxic chemotherapy agent for refractory thymic carcinoma based on a case series, whereas sunitinib or everolimus a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Okuma, Yusuke, Hosomi, Yukio, Miyamoto, Shingo, Shibuya, Masahiko, Okamura, Tatsuru, Hishima, Tsunekazu
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4766615/
https://ncbi.nlm.nih.gov/pubmed/26915359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2159-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky